chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tested positive for COVID-19 after getting the first dose of the Pfizer-BioNTech COVID-19 Vaccine; tested positive for COVID-19 after getting the first dose of the Pfizer-BioNTech COVID-19 Vaccine; hip joints sore; she could not move her body / muscles could not move/ it felt like a magnet was holding her to bed; soreness and pain; Weakness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558). The reporter is the patient.  A female patient received bnt162b2 (COMIRNATY), administration date 30Nov2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 17Dec2021, outcome "unknown" and all described as "tested positive for COVID-19 after getting the first dose of the Pfizer-BioNTech COVID-19 Vaccine"; ASTHENIA (non-serious) with onset Dec2021, outcome "unknown", described as "Weakness"; ARTHRALGIA (non-serious) with onset 17Dec2021, outcome "unknown", described as "hip joints sore"; MOVEMENT DISORDER (non-serious) with onset Dec2021, outcome "unknown", described as "she could not move her body / muscles could not move/ it felt like a magnet was holding her to bed"; PAIN (non-serious) with onset Dec2021, outcome "unknown", described as "soreness and pain". The patient underwent the following laboratory tests and procedures: body temperature: (Dec2021) 99.8, notes: no unit; sars-cov-2 test: (23Dec2021) positive, notes: mouth swab.  Clinical course: Patient received first dose on 30Nov2021 and had muscle pain and weakness a few days later. On 17Dec2021, patient felt tired, fatigue, muscles and hip joints sore. Patient reported that by the time she got home could only sleep. Patient experienced headache and checked her body temperature for fever and noted it was 99.8. Patient stated that she could not move her body and it felt like a magnet was holding her to bed and muscles could not move and painful. Patient was only able to move, get to the bathroom and go back to bed. Patient never experienced anything like this. Patient experienced soreness and pain. Patient contacted her doctor and suspected Covid and to get a Covid test. Patient was tested on 23Dec2021, by mouth swab, on the side of her jaws. On 26Dec2021, test results showed that patient was tested positive for COVID-19. Patient was scheduled for the second dose on 28Dec2021 and is still not feeling 100. Patient felt like she had a cold and coughed up phlegm, like a productive cough.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Left arm is sore.; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 13:45 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration on 24Feb2021 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. On 27Feb2021, the patient underwent nasal swab test for SARS-CoV-2 and result was found to be negative. On 25Mar2021 at 16:00, the patient's left arm was sore. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient had not received treatment for the adverse event. The clinical outcome of the event left arm sore was recovering at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
DTaP administered in r leg on 6-8-2006.  Father brought child into clinic on 6-15-2006 with redness measuring 6 inches x 3 inches with mottling appearance and very hot to touch. Area was firm to touch.  Child did not complain of any pain or fever.  Able to walk on it with no problems.  Child started on Keflex per doctor by phone conversation with myself.  Child then seen in clinic on 6-16-2006 with much improvement of site.  There did appear to be an area at injection site that looked as if the child had scratched that area.
Chronic gout sever flareup; pain in joints; Difficulty walking; Swollen left arm; arm was still red and hot to touch; problem with lymphatics, fluid were not moving; hot to touch; Patient was not able to move left arm; Rash on left arm; Second shot postponed for 67days; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (Patient was not able to move left arm), RASH (Rash on left arm), PERIPHERAL SWELLING (Swollen left arm), ERYTHEMA (arm was still red and hot to touch) and GOUT (Chronic gout sever flareup) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A,) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Gout. Concomitant products included Diltiazem                                                      Hypertension, carafate                                                       Acid reflux and Atenolol                                                       Hypertension for an unknown indication.    On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced MOBILITY DECREASED (Patient was not able to move left arm), RASH (Rash on left arm) and PRODUCT DOSE OMISSION ISSUE (Second shot postponed for 67days). On 27-Mar-2021, the patient experienced PERIPHERAL SWELLING (Swollen left arm), ERYTHEMA (arm was still red and hot to touch), LYMPHATIC DISORDER (problem with lymphatics, fluid were not moving) and SKIN WARM (hot to touch). On 03-Apr-2021, the patient experienced GOUT (Chronic gout sever flareup), ARTHRALGIA (pain in joints) and GAIT DISTURBANCE (Difficulty walking). At the time of the report, MOBILITY DECREASED (Patient was not able to move left arm), RASH (Rash on left arm), PERIPHERAL SWELLING (Swollen left arm), ERYTHEMA (arm was still red and hot to touch), GOUT (Chronic gout sever flareup), ARTHRALGIA (pain in joints), GAIT DISTURBANCE (Difficulty walking), PRODUCT DOSE OMISSION ISSUE (Second shot postponed for 67days), LYMPHATIC DISORDER (problem with lymphatics, fluid were not moving) and SKIN WARM (hot to touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This case was reported by a consumer via call center representative and described the occurrence of back pain in a 84-year-old female patient who received SHINGRIX for prophylaxis. The patient's past medical history included shingles. Concurrent medical conditions included neuralgia. On 19th August 2018, the patient received SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced back pain, neuralgia and condition aggravated. On an unknown date, the outcome of the back pain, neuralgia and condition aggravated were not recovered/not resolved. It was unknown if the reporter considered the back pain, neuralgia and condition aggravated to be related to SHINGRIX. Additional information was received as follows: The batch number and expiry date for SHINGRIX was not reported. The patient experienced rash, that she referenced as shingles rash, experienced by her years ago before vaccination with SHINGRIX, however the patient did not experience any rash after vaccination with SHINGRIX. The patient received the vaccine on the left arm. The patient usually experienced two episodes of post hepatic neuralgia pain in a year but after vaccination with SHINGRIX she had experienced an increase in the frequency of her post hepatic neuralgia episodes that leaded to aggravated condition. The patient stated that she did not remember when the first episode of post hepatic neuralgia started but could have been in late August or September. The patient also experienced intermittent pain in her back, where the patient rated the pain as 7 out of 10 on a pain scale to a 10 out of 10. The patient also added that the pain increased with activity and usually lasted around for four days per episode. On 4th October 2018, the patient saw her doctor for the pain experienced by her. Emergency room visit was required for the patient. The patient provided permission to contact her pharmacist. Consent to follow-up was provided.
Swollen lymph nodes in center of left armpit (same side that I was vaccinated on), painful to the touch and when I move my arm up and down Some breast tenderness/pain (weird feeling) on the same side (left) A bit of tiredness/fatigue
Itching - started nose, then forehead, jaw, neck, chest. Also sense of agitation. Itchy scalp. Jittery, anxious.
Date and time of vaccination: (list both if they received both shots): first jan 19th, second feb 9 coughing is occasional, slightly more than usual started 2/11
pt recvd TD vax for 1st & 2nd degree burns of face approx 3 days later devel pruritic, warm, erythematous rash on lt arm w/o fever; 2 days later came to ER & lesion described as erythematous area on lt arm; knot was palpated @ site of inj
Tested positive for COVID-19; Tested positive for COVID-19; This is a spontaneous report from a contactable consumer (Other HCP) reported for a 42-years-old male patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), intramuscular, administered in Arm Left on 26Apr2021 (at the age of 42-years-old) (Batch/Lot Number: EN6207) as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. It's unknown whether the patient receive any other vaccine in four weeks or within 4 weeks prior to the COVID vaccine, also it was unknown the patient had covid-19 prior vaccination. The patient's Colleague tested positive for COVID on 19Jul2021. The patient was Covid 19 positive (medically significant), The patient underwent lab tests and procedures covid test post vaccination which included sars-cov-2 test (nasal swab): positive on 02Aug2021. The patient received treatment in response to event was unknown. The clinical outcome of events was recovering.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.; Sender's Comments: The information provided is very limited and does not allow for a complete medical assessment. Based on available information a contributory role of BNT162B2 to the reported Covid-19 and Drug ineffective cannot be totally excluded as efficacy of a drug varies from individual to individual depending upon the immune status. Additional information including event onset date, concomitant medications and their indications, concurrent medical conditions, medical history, treatment done, is needed to better assess this report.
Narrative: Patient received Pfizer COVID 19 Vaccine Jan/Feb 2021. The patient tested positive on 9 Sep 21 and was hospitalized due to tremor. During the hospital stay the patient developed sepsis and died on 17 Sep 21. The EUA requires that any patients that tested positive for COVID 19 and required hospitalization after receiving the vaccine must be reported.
Feverish; Achy body; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Feverish) and MYALGIA (Achy body) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 043L20A and D25L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and High cholesterol. Concomitant products included LOSARTAN for Blood pressure high, ATORVASTATIN CALCIUM (AVASTATIN) for High cholesterol.   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (Feverish) and MYALGIA (Achy body). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PYREXIA (Feverish) and MYALGIA (Achy body) had resolved.            Other concomitant medications included Hormone replacement therapy (HRT).  Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-002801 (Patient Link).
Patient received the Moderna vaccine at County Hospital on 01/05/2021 at approx. 12 noon. She continue her work as normal throughout the day.  She began having symptoms around 1700 the same day which consisted of left side facial decrease in sensation that continued to progress until the following day when it plateau'd.  She was seen in the office on 01/06/2021 for continue decreased sensation of the left side of face and left eye pain.  Patient had no other symptoms to mention.  After assessment, the patient was diagnosed with a very mild case of Bell's Palsy.  She was started on a high tapered dose of Prednisone over the next 2 1/2 weeks.
This spontaneous report was received from a registered nurse regarding a patient of unknown age and gender. There was no information on pertinent medical history and drug reactions or allergies. The nurse reported that on 27-MAR-2015, the patient was vaccinated with PNEUMOVAX23, .5 milliliter (ml), product lot#J010654, intramuscularly that expired on 17-OCT-2014. No adverse effects were reported. There was no product quality complaint involved. The outcome of the events was unknown. Additional information has been requested.
Patient complained of flushing after vaccination. Patient denied chest pain, headache, dizziness and no shortness of breath. Cold pack applied.
Appox mid May 2021 noticed a strage feeling when swallowing and slight enlargement of L lymph node.   Lack of other indications decided to give it 2 weeks to resolve.  07 June presented to my PCP, referred to ENT on 10 June.  Subsequent biopsy showed Malignant Neoplasm BOT.  Referred to specialist.
Client reports his left shoulder pain began within 24 hours of vaccine and worsened to the point where it was negatively affecting his work as a contractor. He sought care with an orthopedic surgeon, Dr.  in "early April".  Xray did not show an injury. He was diagnosed with rotator cuff impingement and 3-4 weeks of physical therapy was prescribed.
pt recv vax;had high shrill cry then became pale,limp&apnea;to medical ctr;IV antibiotics started;T 101;hypotensive
Information has been received from a physician via a company representative concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history or concomitant medications were not reported. On 21-FEB-2014, the patient was vaccinated with a dose of PNEUMOVAX 23 2.5 ml, five dose vial (lot number J004332, with an expiration date of 26-SEP-2014) (route and anatomical location of administration were not reported) that was improperly stored. The lowest temperature excursion was of 32 degrees Fahrenheit (F) (0 Celsius) for a total of 72 hours. The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. Furthermore, no product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
got COVID after the 1st shot; got COVID after the 1st shot; This is a spontaneous report from a contactable consumer.  This consumer reported similar events for three patients. This is the second of three reports.  A patient of unspecified age and gender received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported.  On an unknown date, the patient got COVID after the 1st dose. The patient had a positive COVID-19 test on an unknown date. The clinical outcome of patient got COVID after the 1st dose was unknown.   Follow-up (21May2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made.   Follow-up attempts have been completed and no further information is expected.  Follow-up (28May20201): This is a follow-up report to notify that the case 2021503619 and case 2021618698 are duplicates.  All subsequent follow-up information will be reported under Manufacturer report number case 2021618698.  Follow-up attempts have been completed and no further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021503620 same reporter/vaccine, similar events, different patient;US-PFIZER INC-2021503608 same reporter/vaccine, similar events, different patient
Information has been received from the registered nurse on 02-JAN-2014. It was reported that GARDASIL vaccines were stored in improper temperatures and were administered to overall number of 132 patients. This report refers to one of the patients involved: a patient of unspecified age and gender, who was administered dose of GARDASIL on 05-SEP-2013, (lot # H011350, Expiration Date: 21-FEB-2015). No adverse event was reported. This is one of the reports from the same source. Additional information is not expected.
Breakthrough case admission after 2 vaccines Moderna 1/23/21 Lot# 029L20A;  Moderna 2/20/21 Lot# 023M20A
The symptoms were a progressive polyneuropathy. Starting in the feet and progressing fully from head to toe. Included fasciculations in muscles in all regions, loss of position sense, loss of reflex in left ankle, numbness and tingling in feet and legs and progressing to same over whole body.  Some loss of strength in the feet and toes bilaterally.  Test suggest chronic autoimmune polyneuropathy.
sweating started  almost immediately and subsided after 15 minutes, then a few hours later, immense frontal lobe headache, chills, nasea and all over body aches. i used ibuprofen and that helped. today, I all symptoms are still present with the addition of hemoragging in left eye.
Child was eating pizza 1hr after vaccinations, mother noticed that child's upper lip was very swollen and heart rate was slightly increaseed. No trouble breathing.
headache-minor, nonproductive cough, sinus congestion, nasal congestion, post nasal drainage, chest congestion, chest feels sore.starting 11/19/21
Swelling, soreness, large 4? diameter, raised red spot at injection site with larger bruise surrounding it. Itchiness followed X 5 days.   Twelve days post-injection, bruise resolving; itchiness gone; red spot now 2? in diameter  and fading.
Approximately 2 weeks post second Pfizer vaccine developed sensitivity on palm of left hand at base of 4th and 5th digits. On examining area discovered a tiny nodule.  Over next 4 or 5 days this area became more sensitive with swelling, heat and redness - was unable to make a fist.  On 3/21 went to urgent care.  X-ray showed 2  tiny calcifications.  Was advised to see an orthopedic specialist, a PA which I did on 3/22. Diagnosis:  calcific tendonitis.  No previous history of this condition.  Took Meloxicam for 15 days and used ice packs.  Acute condition  subsided but awaiting a visit with   Hand Doctor
Information has been received from a nurse concerning a 9 year old patient who in 1997 was vaccinated with varicella virus vaccine live (Oka/Merck). In May 2007 through 18-JUN-2007, the patient experienced a mild case of chicken pox. The symptoms were mild, a rash on the torso. No VZV titers were taken. No specific treatment was required. Unspecified medical attention was sought. This is one of several reports from the same source. Additional information has been requested.
Patient was give PNEUMOVAX 23 on 09/22/17. Patient complained of lost of feeling/numbness in fingers and having no body strength. He stated that he couldn't button up when dressing due to the lack of strength in his hands and arms. He was seen by his doctor and prescribed muscle relaxer, NSAID, and corticosteroid to treat his symptoms.
Within an hour after receiving the Johnson and Johnson Janssen vaccine, 4 distinct, sharp, rapid, "twisting, pinching" sensations occurred in my cardiac region. I have never experienced anything like this sensation in my life previously. I have described this to multiple physicians and medical personnel taking my health history as feeling that someone had taken a pair of needle-nose pliers and twisted my heart as hard as they could. After that, I could barely walk for about 3 weeks without extreme effort and tremendous fatigue. This was drastically different and in addition to and above my base-line symptoms with the Chronic Fatigue Immune Dysfunction Syndrome (CFIDS). The muscle weakness bordered on paralysis and may have been Guillain-Barre.  Again, the weakness lasted for about 3 weeks and still persists.
was positive for COVID, and negative for influenza a and B.  Chest x-ray showed increased opacities at the right lung base which could represent pneumonitis/pneumonia or increased atelectasis/scarring.  Given concern for cap, patient was initiated on azithromycin and ceftriaxone.
Joints that were swollen became red, hot and more swollen including third toe on left foot, right ankle and foot, left hip, right wrist and right thumb.; hot and more swollen including third, toe on left foot, right ankle and foot, left hip, right wrist and right thumb; hot and more swollen including third, toe on left foot, right ankle and foot, left hip, right wrist and right thumb; Joints that were swollen became red, hot; This is a spontaneous report from a contactable other hcp. A 50-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 25Mar2021 14:30 (Batch/Lot Number: ER8730) as SINGLE DOSE for covid-19 immunisation.  Medical history included Small fiber peripheral neuropathy, Enteropathic  Arthritis Associated With Inflammatory Bowel Disease , vulvodynia, frequent PVCs, allergy with pollen, mold, fungi, dander and dust.  food sensitivities but no true allergies. Patient previously received the first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 04Mar2021, for covid-19 immunization and experienced fatigue and joint swelling.  The patient's concomitant medications were not reported.  The patient experienced joints that were swollen became red, hot and more swollen including third toe on left foot, right ankle and foot, left hip, right wrist and right thumb on 25Mar2021 20:00.  Therapeutic measures were taken as a result of all events. Outcome of all events was not recovered. Case was reported as non-serious.  No Follow-up attempts are needed. No further information is expected.; Sender's Comments: Linked Report(s) : same patient different vaccine dose
Pt had eruption of pustules on erythematous base diffusely (out scattered), worse around head. Lesions were in different stage of healing. Atypical for varicella, but pt had been using steroid cream.